We read with great interest the recently published article titled “Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study” by Wen He et al, which concludes sirolimus can be used as a first-line antiepileptic drug in children with tuberous sclerosis (TSC) and can cause significant gain in development milestones [1]. However, we wish to add a few comments.
19
JUL
JUL
0